
The ARCADIA long-term extension study of over 1,900 patients reveals that nemolizumab remains safe and effective for up to 104 weeks in adolescents and adults with moderate-to-severe atopic dermatitis. The treatment led to lasting improvements in itch, sleep, and skin symptoms, with most side effects mild or moderate and no new safety concerns reported.
Like
Save
Share